First patients in Europe, Israel enrolled in Opthea wet AMD phase 2b study

The first patients in Europe and Israel have been dosed in a phase 2b study of Opthea’s OPT-302 for wet age-related macular degeneration, according to a press release.

OPT-302, a novel VEGF-C/D “trap” therapy, is being evaluated in combination with Lucentis (ranibizumab, Genentech) over a 6-month dosing period.

The ongoing randomized, controlled, international trial is enrolling patients at more than 50 U.S. sites, 50 European sites and six Israeli sites. A total of 351 patients with wet AMD who have not received prior treatment will be enrolled, the release said.

“The activation of clinical trial sites in Europe and Israel represents significant progress in our phase 2b trial,” Megan Baldwin, PhD, CEO and managing director at Opthea, said in the release.

The trial is investigating whether the addition of OPT-302 to Lucentis improves visual acuity and anatomical parameters of wet AMD lesions.

The first patients in Europe and Israel have been dosed in a phase 2b study of Opthea’s OPT-302 for wet age-related macular degeneration, according to a press release.

OPT-302, a novel VEGF-C/D “trap” therapy, is being evaluated in combination with Lucentis (ranibizumab, Genentech) over a 6-month dosing period.

The ongoing randomized, controlled, international trial is enrolling patients at more than 50 U.S. sites, 50 European sites and six Israeli sites. A total of 351 patients with wet AMD who have not received prior treatment will be enrolled, the release said.

“The activation of clinical trial sites in Europe and Israel represents significant progress in our phase 2b trial,” Megan Baldwin, PhD, CEO and managing director at Opthea, said in the release.

The trial is investigating whether the addition of OPT-302 to Lucentis improves visual acuity and anatomical parameters of wet AMD lesions.